Page
%P
-
Article
Open AccessTumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer
Previous small-size studies reported BRAF-mutated NSCLC patients have comparable sensitivity to immune checkpoint inhibitors (ICIs). However, how BRAF mutation affects the tumor immune microenvironment (TIME) is ...